Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cangene Corporation
The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.
Investigational products from Minoryx and a host of other companies targeting a range of diseases are now under review by the European Medicines Agency for potential EU approval.
The Spanish biotech, formed in 2011, is preparing for the potential European launch of leriglitazone for X-linked adrenoleukodystrophy after the EMA accepted its file.
Warning letter reveals agency found quality problems at Emergent BioSolutions’ Camden fill/finish plant during COVID-19 pandemic even as firm’s Bayview plant came under heightened scrutiny. Metal particulates appeared in vials as Camden plant and rest of Emergent’s CDMO network experienced sharp demand growth.
- Contract Research Organization-CRO
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Cangene bioPharma, Inc.
- Chesapeake Biological Laboratories, Inc.
- Twinstrand Therapeutics Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.